ArticleScientific reports2025
Considerations for repetitive intrathecal procedures in long-term nusinersen treatment for non-ambulatory spinal muscular atrophy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Longitudinal Transcriptomic Analysis Reveals Systemic Effects of Risdiplam in Adults with Spinal Muscular Atrophy.Brain sciences · 2026Article
- Neurotoxicological Evaluation of Intrathecal Citrate Excipients: Calcium Homeostasis Disruption and Safety Implications in CNS Drug Delivery.Pharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal muscular atrophy (SMA) is a progressive neuromuscular disorder characterized by progressive motor function loss and skeletal muscular atrophy. Nusinersen, an antisense oligonucleotide, is the first FDA-approved therapy to achieve a significant milestone in SMA management. However, its high molecular weight requires intrathecal administration, posing challenges for clinical implementation. This study aimed to identify factors associated with postprocedural pain following repeated CT-guided transforaminal nusinersen injection in non-ambulatory patients with SMA. This single-center retrospective study evaluated 34 patients who underwent a total of 290 procedures. Postprocedural pain occurred in 49.3% of cases. Factors influencing postprocedural pain included needle angle with vertical and horizontal lines, prophylactic pain control, and number of CT scans (p < 0.05). In patients experiencing postprocedural pain, the needle angle with vertical and horizontal lines emerged as significant variables, with a beta coefficient (standard error) of 0.034 (0.011) (p < 0.05). Needle angle was an important predictor of postprocedural pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.